AstraZeneca: Zoladex®, celebrating 25 years in Australia

---

AstraZeneca has been supporting Australian clinicians and patients with prostate cancer for over 25 years. Zoladex^® was the first LHRH agonist available to treat prostate cancer in Australia.^1,2

---

Zoladex^® is the only LHRH agonist (adjuvant to radiotherapy) proven to demonstrate an overall survival benefit in clinical trials of patients with locally advanced prostate cancer compared to radiotherapy alone.^2-6 Zoladex^® provides a SafeSystem device giving simple one-step administration². For patients requiring Zoladex^® and an antiandrogen, ZolaCos^® CP provides the convenience of a single prescription for combination therapy (Zoladex^® + Cosudex^®)⁷.
AstraZeneca continues to provide support for Australian patients with prostate cancer treated with Zoladex^®:

• The Empower series of educational leaflets provides local expert opinion and guidance on the management of adverse effects and quality of life issues in all men being treated with hormonal therapies for prostate cancer.


• The Frank Patient Support Program uses a straight talking approach about living with prostate cancer, offering a tailored holistic approach to patient support. Patients are provide with educational information on diet, exercise, lifestyle and emotional health. There is regular ongoing contact from a registered support nurse and FRANK magazines filled with relevant articles.

AstraZeneca Australia, based in North Ryde, Sydney, is the second largest pharmaceutical company operating in Australia. AstraZeneca employ almost 1,000 people, are one of the country’s largest manufacturers of medicines and are a key exporter to 35 international markets. AstraZeneca Australia manufactures 100 separate product lines, namely sterile respiratory and local anaesthetic products. Of the top twenty medicines used in Australia, three are made by AstraZeneca. AstraZeneca produces medicines in six separate therapeutic areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience and respiratory inflammation. AstraZeneca contributes significantly to clinical trials in Australia with approximately 50 concurrent trials in 300 sites across the country.

---

References:
1.Data on file, AstraZeneca.
2. Zoladex 10.8 mg Approved Product Information. Date of TGA approval 11 November 2010. Date of most recent amendment 4 September 2012.
3. Bolla M et al. Lancet Oncol 2010; 11(11): 1066–73.
4. Bolla M et al. N Engl J Med 1997; 337: 295–300.
5. Bolla M et al. Lancet 2002; 360: 103–8.
6. Pilepich MC et al. Int J Radiat Oncol Biol Phys 2005; 61: 1285–90.
7. ZolaCos CP Approved Product Information. Date of TGA approval 11 November 2010. Date of most recent amendment 12 May 2014.
^® Zoladex and ZolaCos CP are registered trademarks of the AstraZeneca group of companies. Registered user AstraZeneca Pty. Ltd. ABN 54 009 682 311. 5 Alma Road, North Ryde, NSW 2113. 267001.022 November 2014
For more information phone AstraZeneca Medical on 1800 805 342 or visit www.astrazeneca.com.au